# ESH-convenant polshorloges-bloeddrukmeters: acceptabele nauwkeurigheid, maar klinisch bewijs blijft beperkt

*geplaatst 2026-09-02 · Hypertensie · Journal of hypertension · doi 10.1097/HJH.0000000000004415 · https://hartvaat.nl/2026/10/01/esh-convenant-polshorloges-bloeddrukmeters-acceptabele-nauwkeurigheid-maar-klini/*

De Europese Hypertensie Vereniging (ESH) publiceerde een convenant over polshorloges-bloeddrukmeters met manchettechnologie. Uit een systematische review bleek dat slechts twee apparaten (Omron HeartGuide en Huawei Watch D/D2) voldoen aan strikte validatiestandaarden; statische metingen zijn acceptabel, maar gegevens over 24-uurs monitoring, slaapbloeddruk en speciale populaties zijn nog schaars. Voor de klinische praktijk betekent dit dat deze draagbare apparaten veelbelovend zijn voor zelfmetingen en stressmonitoring, maar dat zorgverleners nog voorzichtig moeten zijn met de interpretatie en dat verder onderzoek naar adherentie en klinische toegevoegde waarde nodig is.

## English: Wearable wrist-watch type cuff oscillometric blood pressure monitors: consensus statement by the European Society of Hypertension Working Group on blood pressure monitoring.

The European Society of Hypertension has issued a consensus statement on wearable wristwatch cuff oscillometric blood pressure monitors. A systematic review identified only two devices (Omron HeartGuide and Huawei Watch D/D2) meeting strict validation standards, with acceptable static accuracy but limited data on 24-hour ambulatory use, sleep BP, and special populations. While these wearables offer potential advantages for home monitoring and stress-related BP episodes, clinicians should exercise caution regarding adherence and measurement accuracy. Further research is needed to establish their clinical utility and role in hypertension management.

## Abstract (original, from the publication)

Wearable wristwatch-type cuff oscillometric blood pressure (BP) monitors represent a new category of BP devices and are the first wearable monitors to use established cuff-oscillometric BP measurement technology. This consensus statement by the European Society of Hypertension Working Group on BP Monitoring reviews the published evidence on their design, accuracy, validation, clinical application, and remaining research questions. Of 281 articles identified through a systematic PubMed search, 26 were relevant. Several devices are currently available; however, only two have published validation studies performed according to established standards (Omron HeartGuide and Huawei Watch D/D2). Static validation studies generally showed acceptable accuracy, whereas data on 24-h ambulatory use, in special populations, and clinical applications remain limited. Potential advantages include self-initiated measurement at home, at work, and in other settings and conditions; more convenient and repeatable 24-h ambulatory monitoring; more convenient and accurate assessment of asleep BP; capture of stress-related and other BP-related episodes. However, proper wrist position, user adherence, ambulatory performance, and clinical applications require further investigation. More research is needed to establish the accuracy and clinical utility of these novel devices and their role in improving the diagnosis and management of hypertension.

Auteurs: George S Stergiou, Ariadni Menti, Kei Asayama, Anastasios Kollias, Gianfranco Parati, Aletta E Schutte, Jiguang Wang, Dagnovar Aristizabal, Roland Asmar, Grzegorz Bilo, Tomas Bothe, Christopher Clark, Kazuomi Kario, Yan Li, Richard McManus, Takayoshi Ohkubo, Paolo Palatini, Dean Picone, Daichi Shimbo, Thomas Tsaganos, Alejandro De La Sierra

---
Bron: Journal of hypertension, https://doi.org/10.1097/HJH.0000000000004415. Bijgewerkt 2026-08-27T00:47:45Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.